Growth opportunity Clinlogix is now part of NAMSA, signaling potential access to expanded global CRO capabilities and cross-sell opportunities across larger client bases in medical devices, pharma, biologics, and diagnostics.

SMB to mid-market With a small team (11-50 employees) and revenue range of 1M-10M, Clinlogix presents a clear target for scalable CRO services, offering tiered engagement models to upgrade clients toward NAMSA’s broader enterprise offerings.

Global reach Regional offices in the US, Europe, Latin America, and Asia Pacific, plus NAMSA affiliation, create a compelling pitch for multinational trials, regulatory consulting, and post-marketing safety surveillance across diverse geographies.

Past collaborations Historical partnerships with Tryp Therapeutics and Urotronic demonstrate Clinlogix’s experience in CNS and device/diagnostics programs, indicating fit for specialty pipelines and complex regulatory pathways.

Tech and data layer Current tech stack including AWS, MySQL, WordPress, and PHP suggests opportunities to offer data integration, secure cloud-enabled study management, and scalable digital solutions to streamline trials for clients seeking modern CRO ecosystems.